1. Home
  2. AGNT vs TECX Comparison

AGNT vs TECX Comparison

Compare AGNT & TECX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo AGNT Inc. Common Stock

AGNT

AGNT Inc. Common Stock

SELL

Current Price

$2.67

Market Cap

468.6M

Sector

Finance

ML Signal

SELL

Logo Tectonic Therapeutic Inc.

TECX

Tectonic Therapeutic Inc.

SELL

Current Price

$20.16

Market Cap

413.3M

Sector

N/A

ML Signal

SELL

Company Overview

Basic Information
Metric
AGNT
TECX
Founded
2008
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
468.6M
413.3M
IPO Year
2010
2018

Fundamental Metrics

Financial Performance
Metric
AGNT
TECX
Price
$2.67
$20.16
Analyst Decision
Buy
Strong Buy
Analyst Count
3
10
Target Price
$5.75
★ $71.00
AVG Volume (30 Days)
★ 1.6M
165.3K
Earning Date
11-05-2026
11-05-2026
Dividend Yield
★ 7.07%
N/A
EPS Growth
N/A
★ 40.70
EPS
★ N/A
N/A
Revenue
★ $500,147,681.00
N/A
Revenue This Year
$3.76
N/A
Revenue Next Year
$7.08
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 220.39
N/A
52 Week Low
$2.67
$16.77
52 Week High
$5.79
$39.53

Technical Indicators

Market Signals
Indicator
AGNT
TECX
Relative Strength Index (RSI) 33.49 40.68
Support Level N/A $18.54
Resistance Level $4.20 $22.95
Average True Range (ATR) 0.29 1.29
MACD -0.11 0.25
Stochastic Oscillator 0.59 34.82

Price Performance

Historical Comparison
AGNT
TECX

About AGNT AGNT Inc. Common Stock

AGNT Inc is a multi-model real estate platform, with brands including eXp Realty, eXp Commercial, NextHome, FrameVR.io, and SUCCESS Enterprises. The group prioritizes transparency, innovation, and long-term value for agents, franchise owners, staff, and shareholders.

About TECX Tectonic Therapeutic Inc.

Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. The company focuses on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.

Share on Social Networks: